Bristol-Myers Squibb Company
Explore Bristol-Myers Squibb
Core profile pages, annual revenue records, and related research hubs for this company.
Bristol-Myers Squibb Company
Explore Bristol-Myers Squibb
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $48.2B
Bristol Myers Squibb makes money through oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines. Its model depends on disciplined capital allocation, durable customer or channel relationships, and execution inside markets where scale and trust matter.
Bristol Myers Squibb is using legacy cash flows from Eliquis, Opdivo, and hematology brands to fund a pipeline reset in oncology, neuroscience, immunology, cell therapy, and radiopharmaceuticals.
Bristol Myers Squibb is known for oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines.
Bristol Myers Squibb reported $48.2B in FY2025 revenue.
Chris Boerner is the current CEO of Bristol Myers Squibb.
Bristol Myers Squibb has about 32,500 employees based on the latest annual reporting context.
The biggest risk is patent-cliff execution: generic pressure on legacy brands must be offset by launches such as Cobenfy, Opdivo Qvantig, Reblozyl, Breyanzi, and radiopharmaceutical programs.